Triple inhaler for COPD with heart risk
Part of Lungs & breathing clinical trials.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, and formoterol) to see if it can help protect the heart and lungs in people with COPD who also have heart problems or high risk for them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have a diagnosis of COPD (confirmed by a breathing test).
- You are a current or former smoker with at least a 10 pack-year smoking history.
- You have a certain level of eosinophils (a type of white blood cell) in your blood.
- You have a score of at least 10 on a COPD symptoms questionnaire.
- You have at least one heart-related condition or risk factor (like high blood pressure, diabetes, or a history of heart disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a triple inhaler (BDP/FF/GB) works for people with severe COPD in Brazil. It may help those who have had at least one flare-up in the past year.
This study compares two ways to deliver long-acting bronchodilator medications for COPD: a nebulizer (machine that turns liquid medicine into a mist) versus a handheld inhaler. The goal is to see which method works better for people with moderate to severe COPD symptoms.
This study looks at whether a breathing test called oscillometry can help guide treatment when switching from two inhaled medicines to triple therapy (including a steroid) for people with COPD who often have flare-ups.
This study tests a triple-combination inhaler (budesonide, glycopyrronium, formoterol) against a placebo inhaler to see how it affects your heart and lungs if you have COPD and over-inflated lungs.
This study tests a new combination inhaler (fluticasone, formoterol, and glycopyrronium) for people with COPD. It aims to see if this triple therapy can improve breathing and quality of life compared to current treatments.
This trial tests a triple combination inhaler (anti-inflammatory plus two bronchodilators) to see if it can improve lung function in people who are showing early signs of chronic lung damage. It might help if you are a smoker with breathing symptoms and your test shows slightly reduced lung function.
Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.